Drugs / PegIFN subcutaneous injection at 180 mcg weekly
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03020004 Background | Jan → Nov 2016 | chronic hepatitis C virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PegIFN subcutaneous injection at 180 mcg weekly | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03020004 ↗ |
| Route | Subcutaneous | “PegIFN subcutaneous injection at 180 mcg weekly” NCT03020004 ↗ |